Nogo-A Receptor Blocking Antibody
Spinal Cord Injury
Phase 1bActive
Key Facts
About NovaGo Therapeutics
NovaGo Therapeutics is a private, clinical-stage biotech company pioneering a novel antibody-based approach to treat spinal cord injury (SCI). Its core technology involves a therapeutic antibody that blocks the Nogo-A receptor to overcome the natural inhibition of nerve regeneration in the central nervous system. Having demonstrated promising preclinical efficacy, the company is advancing towards initial human trials, with a Phase 1b study anticipated to start in 2024. Operating from the major European life sciences hub of Basel, NovaGo is targeting a high-unmet-need neurological condition with no approved disease-modifying therapies.
View full company profileTherapeutic Areas
Other Spinal Cord Injury Drugs
| Drug | Company | Phase |
|---|---|---|
| MSC‑SCI | Advancells | Phase 1 |
| itNSCs | Stemedica Cell Technologies | Development |
| MAP4343 | Mapreg | Preclinical |
| Spinal Cord Injury Program | BioAxone Biosciences | Clinical |
| Undisclosed Scaffold Program | Innervace | Pre-clinical |
| Q-Cells | Q Therapeutics | Research |
| APOSEC | Aposcience | Pre-clinical |
| NG004 | Neurimmune | Phase 1 |
| Perineline™ | NeuroSolv Therapeutics | Phase 1 |
| Spinal Cord Injury (SCI) Neural Bridge | Matricelf | Preclinical |